Home > News > A Review of Treatment in Non-small-cell Lung Cancer
Lung Cancer
Read Time: 2 mins

A Review of Treatment in Non-small-cell Lung Cancer

Published Online: August 5th 2012 European Oncology & Haematology, 2012;8(4):208-212 DOI: https://doi.org/10.17925/EOH.2012.08.4.208
Authors: Athanasios G Pallis
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Non-small-cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancer cases. For patients with early-stage disease, surgery followed by adjuvant chemotherapy is the optimal treatment. For patients with locally advanced disease, the standard approach is chemoradiotherapy, since it offers a small but statistically significant prolongation in survival compared with the sequential approach. It should be noted, however, that this approach is associated with significant toxicity and it only applies to patients with good performance status. For patients with metastatic disease, chemotherapy represents the cornerstone of treatment and results in a median survival of approximately 10 months. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets and the use of gefitinib and erlotinib has improved the outcome in selected patients with advanced NSCLC. Hopefully, advances in understanding the molecular biology of cancer and mechanisms of tumourigenesis will facilitate the discovery and development of novel ‘targeted agents’ and will further improve outcomes for these patients.

Keywords

Lung carcinoma, non-small-cell lung cancer (NSCLC), adjuvant, chemotherapy, targeted agents, erlotinib, maintenance treatment, gefitinib, bevacizumab

Article:

The term lung cancer refers to carcinomas that originate from the respiratory epithelium. Approximately 85 % of all lung cancers are classified as non-small-cell lung cancer (NSCLC), 10 % are small cell lung cancer and other histological variants account for about 5 %.1 Lung cancer represents the second most common type of cancer in both men (after prostate cancer) and women (after breast cancer) in the Western world.1 It is estimated that approximately 220,000 new cases of lung cancer occurred during 2009 in the US.1,2 Both the absolute and relative frequency of lung cancer has risen dramatically, for example the age-adjusted death rates from lung cancer were similar to that of pancreatic cancer prior to 1930 for men and prior to 1960 for women.1 Although the incidence of lung cancer is declining in men, it continues to rise in women.1 Unfortunately, lung cancer remains by far the most frequent cause of cancer-related death, with approximately 159,000 deaths observed in 2009 in the US.1 By contrast, colorectal, breast and prostate cancers combined will have been responsible for only 118,000 deaths.1 Although lung cancer deaths have begun to decline in men, the death rate in women continues to rise and almost half of all lung cancer deaths now occur in women.1 The vast majority of patients are diagnosed with advanced, unresectable disease that remains incurable. This has a five-year survival rate of <5 %,3 whereas the five-year survival rate for all stages is approximately 15 %.4

Data linking cigarette smoking to human lung cancer include a huge bank of both prospective and retrospective epidemiological research first reported in 1950.5–7 A heavy smoker is considered to have a cumulative lung cancer risk as high as 30 % compared with a lifetime risk of lung cancer of ≤1 % in people who have never smoked.8 The relative risk of lung cancer development in a long-term smoker compared with someone who has never smoked is estimated to be 10- to 30-fold greater.8 The relative risk increases with both the number of cigarettes smoked per day as well as the lifetime duration of smoking. Smoking cessation clearly decreases the risk of lung cancer among former smokers compared with current smokers.9 The reduction in risk becomes evident within five years of becoming abstinent and it has been estimated that former smokers who have been abstinent for >15 years have an 80–90 % reduction in risk of lung cancer compared with current smokers.8 Environmental tobacco smoke (i.e. passive or ‘second-hand’ exposure) is associated with an increase in the risk of lung cancer, although this increase is far lower than that observed with active smoking.10,11 The purpose of this article is to present current data regarding the treatment of NSCLC.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Disclosure

Athanasios G Pallis has served as a consultant for AstraZeneca.

Correspondence

Athanasios G Pallis, Medical Oncologist, Department of Medical Oncology, University General Hospital of Heraklion, 711 10 Heraklion, Crete, Greece. E: agpallis@gmail.com

Received

2010-12-07T00:00:00

References

  1. Jemal A, Siegel R, Ward E, et al., Cancer statistics, 2009, CA Cancer J Clin, 2009;59(4):225–49.
  2. Parkin DM, Bray F, Ferlay J, et al., Global cancer statistics, 2002, CA Cancer J Clin, 2005;55(2):74–108.
  3. Yang P, Allen MS, Aubry MC, et al., Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003, Chest, 2005;128(1):452–62.
  4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006, CA Cancer J Clin, 2006;56(2):106–30.
  5. Doll R, Hill AB, Smoking and carcinoma of the lung; preliminary report, Br Med J, 1950;2(4682):739–48.
  6. Doll R, Peto R, Boreham J, et al., Mortality in relation to smoking: 50 years’ observations on male British doctors, BMJ, 2004;328(7455):1519.
  7. The Health Consequences of Smoking: A Report of the Surgeon General, US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, Washington, DC, 2004. Available at: www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm (accessed 18 January 2011).
  8. Samet JM, Health benefits of smoking cessation, Clin Chest Med, 1991;12(4):669–79.
  9. The Health Consequences of Smoking: A Report of the Surgeon General, US Department of Health and Human Services, Washington, 1990.
  10. Fontham ET, Correa P, Reynolds P, et al., Environmental tobacco smoke and lung cancer in nonsmoking women. A multicenter study, JAMA, 1994;271(22):1752–9.
  11. Janerich DT, Thompson WD, Varela LR, et al., Lung cancer and exposure to tobacco smoke in the household, N Engl J Med, 1990;323(10):632–6.
  12. Scott WJ, Howington J, Feigenberg S, et al., Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 2007;132(3 Suppl):234S–42S.
  13. Ginsberg RJ, Rubinstein LV, Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group, Ann Thorac Surg, 1995;57(3):615–22.
  14. Mery CM, Pappas AN, Bueno R, et al., Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database, Chest, 2005;128(1):237–45.
  15. Rowell NP, Williams CJ, Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review, Thorax, 2001;56(8):628–38.
  16. Rowell NP, Williams CJ, Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable), Cochrane Database Syst Rev, 2001;(2):CD002935.
  17. Winton T, Livingston R, Johnson D, et al., Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer, N Engl J Med, 2005;352(25):2589–97.
  18. Douillard JY, Rosell R, De LM, et al., Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial, Lancet Oncol, 2006;7(9):719–27.
  19. Pignon JP, Tribodet H, Scagliotti GV, et al., Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE Collaborative Group, J Clin Oncol, 2008;26(21):3552–9.
  20. Scagliotti GV, Fossati R, Torri V, et al., Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer, J Natl Cancer Inst, 2003;95(19):1453–61.
  21. Arriagada R, Bergman B, Dunant A, et al., Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer, N Engl J Med, 2004;350(4):351–60.
  22. Waller D, Peake MD, Stephens RJ, et al., Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial, Eur J Cardiotorac Surg, 2004;26(1):173–82.
  23. Strauss GM, Herndon JE, Maddaus MA, et al., Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups, J Clin Oncol, 2008;26(31):5043–51.
  24. Arriagada R, Auperin A, Burdett S, et al., Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data, Lancet, 2010;375(9722):1267–77.
  25. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group, Lancet, 1998;352(9124):257–63.
  26. Burdett S, Stewart L, Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis, Lung Cancer, 2005;47(1):81–3.
  27. Mayer R, Smolle-Juettner FM, Szolar D, et al., Postoperative radiotherapy in radically resected non-small cell lung cancer, Chest, 1997;112(4):954–9.
  28. Dautzenberg B, Arriagada R, Chammard AB, et al., A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d’Etude et de Traitement des Cancers Bronchiques, Cancer, 1999;86(2):265–73.
  29. Feng QF, Wang M, Wang LJ, et al., A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial, Int J Radiat Oncol Biol Phys, 2000;47(4):925–9.
  30. Okawara G, Ung YC, Markman BR, et al., Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline, Lung Cancer, 2004;44(1):1–11.
  31. Pisters KM, Evans WK, Azzoli CG, et al., Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline, J Clin Oncol, 2007;25(34):5506–18.
  32. Robinson LA, Ruckdeschel JC, Wagner H, Jr, et al., Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 2007;132(Suppl. 3):243S–65S.
  33. Furuse K, Fukuoka M, Kawahara M, et al., Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer, J Clin Oncol, 1999;17(9):2692–99.
  34. Curran WJ, Scott CB, Langer CJ, Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410, Proc Am Soc Clin Oncol, 2003;22(621):abstract no. 2499.
  35. Pfister DG, Johnson DH, Azzoli CG, et al., American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003, J Clin Oncol, 2004;22(2):330–53.
  36. van Meerbeeck JP, Kramer GW, Van Schil PE, et al., Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer, J Natl Cancer Inst, 2007;99(6):442–50.
  37. Albain KS, Swann RS, Rusch VW, et al., Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial, Lancet, 2009;374(9687):379–86.
  38. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials, J Clin Oncol, 2008;26(28):4617–25.
  39. Lilenbaum RC, Herndon JE, List MA, et al., Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730), J Clin Oncol, 2005;23(1):190–6.
  40. Delbaldo C, Michiels S, Syz N, et al., Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis, JAMA, 2004;292(4):470–84.
  41. Azzoli CG, Baker S Jr, Temin S, et al., American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer, J Clin Oncol, 2009;27(36):6251–66.
  42. Schiller JH, Harrington D, Belani CP, et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 2002;346(2):92–8.
  43. NCCN Clinical Practice Guidelines in Oncology. v.2.2010 Non- Small-Cell Lung Cancer, National Comprehensive Cancer Network, 2010. Available at: https://www.nccn.org /professionals/physician_gls/f_guidelines.asp (accessed 18 January 2011).
  44. Scagliotti GV, Parikh P, von PJ, et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 2008;26(21):3543–51.
  45. Folkman J, Role of angiogenesis in tumor growth and metastasis, Semin Oncol, 2002;29(6 Suppl. 16):15–8.
  46. Poon RT, Fan ST, Wong J, Clinical implications of circulating angiogenic factors in cancer patients, J Clin Oncol, 2001;19(4):1207–25.
  47. Pallis AG, Serfass L, Dziadziusko R, et al., Targeted therapies in the treatment of advanced/metastatic NSCLC, Eur J Cancer, 2009;45(14):2473–87.
  48. Reck M, von PJ, Zatloukal P, et al., Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil, J Clin Oncol, 2009;27(8):1227–34.
  49. Sandler A, Gray R, Perry MC, et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 2006;355(24):2542–50.
  50. Crino L, Dansin E, Garrido P, et al., Safety and efficacy of first-line bevacizumab-based therapy in advanced nonsquamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study, Lancet Oncol, 2010;11(8):733–40.
  51. Fischbach NA, Spigel D, Brahmer J, et al., Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS), J Clin Oncol, 2009;27(15s):abstract 8040.
  52. Ciardiello F, Tortora G, EGFR antagonists in cancer treatment, N Engl J Med, 2008;358(11):1160–74.
  53. Citri A, Yarden Y, EGF-ERBB signalling: towards the systems level, Nat Rev Mol Cell Biol, 2006;7(7):505–16.
  54. Pirker R, Pereira JR, Szczesna A, et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 2009;373(9674):1525–31.
  55. Lynch TJ, Patel T, Dreisbach L, et al., Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099, J Clin Oncol, 2010;28(6):911–7.
  56. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 2004;350(21):2129–39.
  57. Paez JG, Jänne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 2004;304(5676):1497–500.
  58. Miller VA, Riely GJ, Zakowski MF, et al., Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib, J Clin Oncol, 2008;26(9):1472–8.
  59. Tamura K, Okamoto I, Kashii T, et al., Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403), Br J Cancer, 2008;98(5):907–14.
  60. Yoshida K, Yatabe Y, Park JY, et al., Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer, J Thorac Oncol, 2007;2(1):22–8.
  61. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 2009;361(10):947–57.
  62. Mitsudomi T, Morita S, Yatabe Y, et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 2010;11(2):121–8.
  63. Maemondo M, Inoue A, Kobayashi K, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 2010;362(25):2380–8.
  64. Zhou C, Wu YL, Chen G, et al., Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (Cbdca) plus gemcitabine (Gem), in Chinese advanced non-small-cell lung cancer (Nsclc) patients (Pts) with Egfr activating mutations, Ann Oncol, 2010;21(Suppl. 8):abstract LBA 13.
  65. Fidias PM, Dakhil SR, Lyss AP, et al., Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer, J Clin Oncol, 2009;27(4):591–8.
  66. Ciuleanu T, Brodowicz T, Zielinski C, et al., Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 2009;374(9699):1432–40.
  67. Cappuzzo F, Ciuleanu T, Stelmakh L, et al., Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, Lancet Oncol, 2010;11(6):521–9.
  68. Kabbinavar F, Miller VA, Johnson BE, et al., for the ATLAS investigators, Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC), J Clin Oncol, 2010;28(15s):abstract 7526.
  69. Miller VA, O’Connor P, Soh C, et al., for the ATLAS investigators, A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC), J Clin Oncol, 2009;27(18s):LBA8002.
  70. Shepherd FA, Dancey J, Ramlau R, et al., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 2000;18(10):2095–103.
  71. Hanna N, Shepherd FA, Fossella FV, et al., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 2004;22(9):1589–97.
  72. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al., Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 2005;353(2):123–32.
  73. Kim ES, Hirsh V, Mok T, et al., Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 2008;372(9652):1809–18.

Further Resources

Share this Article
Related Content In Lung Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72